This document provides information about infertility, including its definition, types, etiology, evaluation, and treatment. Some key points:
- Infertility is defined as the inability to conceive after one year of regular unprotected intercourse. Its incidence is 15-30% of couples.
- Etiology can include male factors (30%), female factors (45%), and combined or unexplained causes.
- Evaluation of male infertility involves history, physical exam, semen analysis, and potential further tests. Evaluation of female infertility involves history and physical exam and may include hormonal and imaging tests.
- Treatment depends on the underlying cause but can include lifestyle changes, medication, surgery, assisted reproductive technologies like IUI
INFERTILITY: Failure to conceive within one or more years of regular unprotected coitus.
PRIMARY INFERTILITY: Patients who have never conceived
SECONDARY INFERTILITY : Previous pregnancies but failure to conceive subsequently
INFERTILITY: Failure to conceive within one or more years of regular unprotected coitus.
PRIMARY INFERTILITY: Patients who have never conceived
SECONDARY INFERTILITY : Previous pregnancies but failure to conceive subsequently
The cause for infertility could be in the male or the female or both or neither-as in ‘Unexplained Infertility.’
Male infertility is usually caused by problems that affect either sperm production or sperm transport.
The cause for infertility could be in the male or the female or both or neither-as in ‘Unexplained Infertility.’
Male infertility is usually caused by problems that affect either sperm production or sperm transport.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
2. DEFINITION
• After one year of frequent, unprotected
sexual intercourse there is no conception or
maintenance of pregnancy
• INCIDENCE : 15 – 30% couples
3. SUBFERTILITY
• Inability to conceive after one year of
regular unprotected intercourse in the
absence of known reproductive pathology.
• Peak monthly pregnancy rate ~ 30%
• Cumulative rate in 1 year ~ 85%
• Cumulative rate in 2 years ~ 95%
4. • FECUNDABILITY : probability that a cycle
will result in pregnancy.
• FECUNDITY : probability that a cycle will
result in a live birth.
• In a normal fertile couple - 20% to 30%
5. Types of Infertility
• PRIMARY INFERTILITY: Patients who
have never conceived
• SECONDARY INFERTILITY : Previous
pregnancies but failure to conceive
subsequently
6. ETIOLOGY
• Male factors: 30%
• Female: 45%
• Tubal: 20%
• Ovulatory disorders: 25%
• Uterine: 10%
• Endometriosis: 5%
• Unexplained:25%
• Combined male and female: 40%
14. HISTORY
Focuses on causes of infertility.
• Personal:
Age, occupation, special habits
• Present:
Type of infertility, duration
• Sexual:
Frequency, erection, ejaculation, dysparunia,
habits, libido.
15. History
Past:
• Medical:
Chronic medical illness
Infections: mumps orchitis, sinopulmonary symptoms,
STI, and GUI (prostatitis)
• Surgical:
inguinal and scrotal areas such as vasectomy,
orchiectomy, and herniorrhaphy
• Trauma
• Developmental:
testicular descent, pubertal development, loss of body
hair, or decrease in shaving frequency
16. History
• Drugs and environmental exposures
alcohol, radiation therapy, anabolic steroids,
cytotoxic chemotherapy, drugs that cause
hyperprolactinemia, exposure to toxic
chemicals.
• School performance : determine if he has a
history of learning disabilities
17. Examination
• General physical examination : general built ,
nutrition, skin & hair, sec sexual characteristics,
habitus & breast development.
• Examination of penis, location of urethral
meatus
• Palpation of testes & size
• Presence & consistency of vas & epididymis
• Digital rectal Examination
19. Normal Semen Analysis Results
(WHO)
• Volume >2ml
• pH 7-8
• Concentration >20 x 106/ml
• Motility >50% forward & >25% with
rapid linear progress
• Morphology > 15% normal
• Alive > 50%
• Antisperm antibodies Negative
• WCC < 1x106
20. • II. SPECIALIZED SEMEN ANALYSIS
Not routinely performed
used to determine the cause of male infertility
• 1. Sperm autoantibodies
• 2. Semen Fructose
• 3. Semen culture
• 4. Sperm function tests
CASA
SDNAF
21. Investigations
• III. ENDOCRINE
TESTS
1. Testosterone
2. LH and FSH
3. Prolactin
• IV. GENETIC TESTS
1. Karyotyping
2. Y chromosome
microdeletions
3. Cystic fibrosis
conductance regulator
(CFTR) gene mutation
30. SURGICAL TREATMENT
1. Vasovasostomy & vasoepididymostomy- In
vasectomized men
2. Transurethral resection of the ejaculatory ducts- in
men with Ejaculatory duct obstruction.
3. Varicocele repair- In men with varicoceles.
4. Orchipexy – In cryptorchidism
5. Vibratory stimulation & Electroejaculation – In
neurological dysfunctions
34. Implementation and
Collaborative Care
• Sperm Washing for Intrauterine
Insemination (IUI)
– Ejaculate is centrifuged to concentrate sperm,
which are then rinsed with saline to remove the
seminal fluid
– Sperm are again centrifuged, and then used for
either IVF or Intrauterine artificial insemination
36. Implementation and
Collaborative Care
• Intrauterine Insemination (a form of
artificial insemination)
– Sperm are collected within 3 hours of colitus
and are inserted via a catheter into the uterus
– Donor sperm may be used
– Identify of the sperm donor is kept confidential
37. Donor Sperm
INDICATIONS :
• 1. Azoospermia
• 2. Immunological factors not correctable
• 3. Genetic disease in husband
43. PCOS
Rotterdam Criteria (2 out of 3)
Menstrual irregularity due to
anovulation or oligo-ovulation
Evidence of clinical or biochemical
hyperandrogenism
Polycystic ovaries by US
• presence of 12 or more follicles in each ovary
measuring 2 to 9 mm in diameter and/or increased
ovarian volume.
45. Tubal factors
• Tubal disease and pelvic adhesions prevent
normal transport of the oocyte and sperm
through the fallopian tube.
• PID
• Severe endometriosis
• Previous surgery or non-tubal infection (eg,
appendicitis, inflammatory bowel disease),
• Pelvic TB
48. Uterine factors
Impaired implantation, either mechanical or
due to reduced endometrial receptivity, are the
basis of uterine causes of infertility.
Uterine leiomyomata:A meta-analysis showed
that only leiomyomata with a submucosal or
intracavitary component were associated with
lower pregnancy and implantation rates.
49. Uterine anomalies; Uterine abnormalities are
thought to cause infertility by interfering with
normal implantation. Müllerian anomalies are a
significant cause of (RPL), with the septate
uterus associated with the poorest reproductive
outcome .
Other structural abnormalities
endometrial polyps
synechiae from prior pregnancy related
curettage.
50. CERVICAL FACTORS
Normal midcycle cervical mucus
facilitates the transport of sperm.
Congenital malformations and trauma
to the cervix (including surgery) may result in
stenosis and inability of the cervix to produce
normal mucus, thereby impairing fertility.
51. UNEXPLAINED
Unexplained infertility is the diagnosis
given to couples after a thorough evaluation
has not revealed a cause.
Many cases of unexplained infertility may
be due to small contributions from multiple
factors.
52. History-General
• Both couples should be present
• Age
• Previous pregnancies by each partner
• Duration of infertility
• Sexual history
Frequency and timing of intercourse
Use of lubricants
Impotence, dyspareunia
• Contraceptive history
53. History-Female
• Previous female pelvic surgery
• PID
• Appendicitis
• IUD use
• Ectopic pregnancy history
• Endometriosis
• Leiomyoma
54. History
• Irregular menses, amenorrhea, detailed
menstrual history
• Molimina
• Vasomotor symptoms
• Changes of hair growth, breast discharge
• Stress
• Weight changes
• Exercise-drug –radiation -chemotherapy
• Cervical and uterine surgery
56. Investigations
Assessment of ovulation
• Basal body temperature
• Urine LH kits
• Mid luteal serum progesterone
• Routine hormonal profile: FSH, LH,Prolactin,TSH
• Endometrial biopsy
• Serial pelvic Ultrasonography
57.
58. • Evidence of ovulation:
1. Menstrual history of regular cycles.
2. Serum progesterone in the mid-luteal phase of
their cycle (day 21 of a 28-day cycle) even if they
have regular menstrual cycles.
3. Serum gonadotrophins ( FSH & LH) on Day2-3
especially in irregular periods.
No role for basal body temperature
59. Ovarian reserve tests
More important in >35 years old, suspected ovarian
failure and to detect response to ovulation induction.
• 1. Total antral follicle count.
• 2. AMH of less than or equal to 5.4 pmol/l for a
low response and greater than or equal to 25 pmol/l
for a high response
• 3. FSH greater than 8.9 IU/l for a low response
and less than 4 IU/l for a high response.
62. Diagnostic Studies –
Female
• Hysterosalpingogram (HSG)
– Detects uterine anomalies (septate, unicornate,
bicornate)
– Detects Tubal anomalies or blockage
– Iodine-based radio-opaque dye is instilled
through a catheter into the uterus and tubes to
outline these structures and x-rays are taken to
document findings
65. Diagnostic Studies –
Female
• Laparoscopy
– General or epidual anesthesia
– Abdomen is insufflated with carbon dioxide
– One or more trochars are inserted into the
peritoneum near the umbilicus & symphysis
pubis
– Laparoscope visualizes structures in the pelvis
– Can perform certain surgical procedures
66.
67.
68. Assessment of the uterine cavity
Modalities to assess the uterine cavity include
• Saline Infusion Sono-hysterography (SIS)
• Three dimensional sonography
• Hysterosalpingography (HSG)
• Hysteroscopy
69. Investigations NOT indicated in
clinical practice
• Serum antisperm antibody
• Postcoital test
• Sperm function test
• Endometrial biopsy
• Hysteroscopy
• Ultrasound of endometrium
70.
71.
72. Treatment of female infertility
General advice
• folic acid whilst trying to conceive and
during the first 12 wks of pregnancy to
prevent neural tube defects
• Reduce body weight in obese women
• Stop smoking
• Avoid excessive alcohol
73. Good health
Free from illness eg thyroid, blood pressure,
diabetes
Avoid food fads
Balanced diet
Folic Acid
Supplements
75. Management of Hypothalamic
pituitary failure
Amenorrhea or severe oligomenorrhea
FSH & LH: low
Prolactin: normal
• 1. Reverse the life style factors:
• Increase wt if BMI <19
• Moderating exercise if high levels of exercise.
• Treat stress
• 2. Gonadotrphins with LH activity or Pulsatile
GnRH (pump)
77. Clomiphene Citrate (cc)
• 1) Starting dose is 50 mg daily for 5 days, can be started
b/t day 2- 6 of menses,
• 2) Check for ovulation
• 3) If there is ovulation, continue the same dose for 3-6
cycles, either with timed coitus or with IUI.
• 4) No response, increase dose by 50 mg in each cycle,
until a maximum of 150mg per day.
• 5) If no response to the maximum dose, further increase
is not effective
78. Gonadotrophin therapy
In women with PCOD
Aim:
• Ripen follicles with repeated doses of FSH
• Stimulate ovulation with injection of LH or hCG
Drugs in use:
• HMG– 75 IU FSH, 25-75 iu LH
• Urofollitrophin—75 IU FSH n almost no LH
• Recombinant FSH—75 IU FSH
• hCG—1000-5000 IU hCG
81. Management of Tubal Factors
Tubal surgery
• microsurgical technique
• laparotomy or laparoscopy
• adhesiolysis, re-anastomosis,
salpingostomy
• In vitro fertilization and embryo transfer
(IVF-ET)
83. Management of Uterine Factors
• Septate uterus
Not increased among women with infertility
compared with other women (2–3%).
More common: RM or PTL.
• Hysteroscopic metroplasty:
84. Management of Uterine Factors
Intrauterine adhesions with amenorrhoea
• hysteroscopic adhesiolysis